ArticleMolecular cancer therapeutics2022

Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers.

Maija Hollmén et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.